<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023681</url>
  </required_header>
  <id_info>
    <org_study_id>014</org_study_id>
    <nct_id>NCT05023681</nct_id>
  </id_info>
  <brief_title>Efficacy of an Early Phase Single Bolus r-SAK for Acute Myocardial Infarction: a Multi-center Randomized Clinical Trial</brief_title>
  <official_title>Efficacy of an Early Phase Single Bolus r-SAK for Acute Myocardial Infarction: a Multi-center Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarction (AMI) is one of the leading causes of death all over the world.&#xD;
      Even if patients with AMI survive the acute period without death, some ones would inevitably&#xD;
      develop into chronic heart failure due to myocardial ischemia caused by segmental ventricular&#xD;
      wall dyskinesia, myocardial remodeling, etc., which would seriously affect the prognosis of&#xD;
      these patients. Early intensive treatment is the decisive factor to reduce the death of&#xD;
      patients with AMI. However, the primary hospitals where patients firstly visit do not have&#xD;
      the ability of Primary Percutaneous Transluminal Coronary Intervention (PCI) the guidelines&#xD;
      recommend. They have to transport patients to a center that has the conditions for emergency&#xD;
      interventional treatment. But this transportation will delay a lot of time, resulting in the&#xD;
      extension of MI area. More importantly, the thrombus load in coronary arteries would increase&#xD;
      with time, and the implantation of stents in vessels with a large thrombus load will often&#xD;
      lead to slow flow or no flow, which is a relative contraindication for interventional&#xD;
      therapy.&#xD;
&#xD;
      At present, the guidelines recommend loading dose antiplatelet therapy and transport to the&#xD;
      superior hospital for prime PCI within 2 hours if the first hospital for acute myocardial&#xD;
      infarction does not have the conditions for emergency interventional therapy. Current&#xD;
      guidelines recommend that thrombolytic therapy should be performed first and then transported&#xD;
      when delivery is expected to be &gt;2 hours to a hospital where PCI can be performed. And&#xD;
      thrombolytic therapy is not recommended for patients who can perform PCI within &lt;2 hours.&#xD;
      There is a lack of clinical evidence for thrombolysis within 2 hours of first medical contact&#xD;
      to Primary PCI. Compared with Primary PCI, early thrombolytic therapy can undoubtedly shorten&#xD;
      the implementation time of reperfusion strategy to the maximum. For highly effective&#xD;
      thrombolytic drugs, reperfusion time should be shortened, thrombus load should be reduced,&#xD;
      and the size of myocardial infarction may be reduced and the prognosis of patients improved.&#xD;
      There is a lack of clinical evidence for this. China is a developing country, whose&#xD;
      grassroots and rural health resources are still poor. Early thrombolysis treatment plus&#xD;
      subsequent reperfusion of interventional therapy not only conform to the Chinese&#xD;
      characteristic, but also accord with the international research and the development direction&#xD;
      in this field, which is worth further study.&#xD;
&#xD;
      Staphylokinase (SAK) is produced by Staphylococcus aureus and it is a protein containing 136&#xD;
      amino acid residues. Its ability for dissolving blood clots was first discovered in 1948.&#xD;
      Studies have shown that SAK is not directly convert plasminogen (PLG) into plasminogen (PLi),&#xD;
      but first combines with PLG in a 1:1 ratio to form a complex. The complex can lead to the&#xD;
      exposure of PLG active site, from single chain to double chain PLi, resulting to form an&#xD;
      active SAK-PLI complex, which subsequently activates PLG molecules. Then PLG transforms into&#xD;
      PLi and further dissolve the thrombus.&#xD;
&#xD;
      Recombinant SAK (r-SAK) was developed in 1990 by Shanghai Institute of Plant and Biological&#xD;
      Physiology. It is a gene recombinant drug prepared by molecular cloning of SAK gene in&#xD;
      Escherichia coli. Its biological characteristics are very similar to natural SAK, and r-SAK&#xD;
      is a highly fibrin-specific fibrinolysis agent. R-SAK is considered to be one of the most&#xD;
      promising thrombolytic drugs due to its high thrombolysis activity (especially in&#xD;
      platelet-rich arterial thrombosis), inactivation of system fibrinolysis, and few side&#xD;
      effects. Clinical studies have shown that the efficacy of r-SAK in the treatment of AMI is&#xD;
      better than urokinase, comparable to RT-PA, and it does not increase serious bleeding&#xD;
      complications such as intracranial hemorrhage.&#xD;
&#xD;
      In terms of pharmacokinetics, r-SAK has a fast distribution and a long action time in human&#xD;
      body. Half-lives of distribution term is 13.30±2.06min and elimination term is 67.94±21.39min&#xD;
      when intravenous injection 10 mg r-SAK in 30min. A single bolus of r-SAK as early as possible&#xD;
      during the first medical contact (such as prehospital care or primary hospitals or medical&#xD;
      centers with conditional PCI) can maximize the time window for reperfusion therapy. R-SAK, a&#xD;
      highly effective thrombolytic drug, may shorten the reperfusion time, reduce the size of&#xD;
      myocardial infarction and improve the prognosis of the AMI patients.&#xD;
&#xD;
      The aim of this study was to investigate the efficacy of single bolus of r-SAK for&#xD;
      thrombolytic therapy at the first contact with the patients who are diagnosed acute&#xD;
      ST-segment elevation myocardial infarction. It is hypothesized that this therapy can open the&#xD;
      culprit artery very early and effectively, reduce thrombus load, reduce slow flow or no flow&#xD;
      caused by subsequent PCI, and improve myocardial tissue perfusion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>In this study, patients are randomly assigned 1:1 to the r-SAK treatment group and the saline control group using a central randomization system.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total rate of TIMI grade 3 + TIMI grade 2 of blood flow in coronary angiography after 60 minutes of use of study medication</measure>
    <time_frame>60min</time_frame>
    <description>Total rate of TIMI grade 3 + TIMI grade 2 of blood flow in coronary angiography after 60 minutes of use of study medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of TIMI grade 3 of blood flow in coronary angiography after 60 minutes of use of study medication</measure>
    <time_frame>60min</time_frame>
    <description>Rate of TIMI grade 3 of blood flow in coronary angiography after 60 minutes of use of study medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total rate of TIMI grade 3 + TIMI grade 2 of blood flow in the first coronary angiography after use of study medication</measure>
    <time_frame>60min</time_frame>
    <description>Total rate of TIMI grade 3 + TIMI grade 2 of blood flow in the first coronary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital MACE events (all-cause death, non-fatal myocardial infarction, ischemic stroke, emergency target vessel revascularization)</measure>
    <time_frame>30days</time_frame>
    <description>In-hospital MACE events (all-cause death, non-fatal myocardial infarction, ischemic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events above BARCIII during hospitalization</measure>
    <time_frame>30days</time_frame>
    <description>Bleeding events above BARCIII during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit of MACE events and bleeding events above BARCIII during hospitalization</measure>
    <time_frame>30days</time_frame>
    <description>Clinical benefit of MACE events and bleeding events above BARCIII during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE event within 30 days after AMI</measure>
    <time_frame>30days</time_frame>
    <description>MACE event within 30 days after AMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit due to death, rehospitalization, repeat myocardial infarction, emergency target vessel revascularization, ischemic stroke, and bleeding events above BARCIII within 30 days after AMI</measure>
    <time_frame>30days</time_frame>
    <description>Clinical benefit due to death, rehospitalization, repeat myocardial infarction,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction area, microvascular embolism, and cardiac function (EF) detected by MRI 7 days after AMI</measure>
    <time_frame>7days</time_frame>
    <description>Myocardial infarction area, microvascular embolism, and cardiac function (EF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All bleeding events occurred up to 30 days after administration of the study drug</measure>
    <time_frame>30days</time_frame>
    <description>All bleeding events occurred up to 30 days after administration of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BARCIII or above bleeding events occurred 30 days after the administration of the study drug</measure>
    <time_frame>30days</time_frame>
    <description>BARCIII or above bleeding events occurred 30 days after the administration of the study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI Grade 3 blood flow ratio after emergency PCI</measure>
    <time_frame>30days</time_frame>
    <description>TIMI Grade 3 blood flow ratio after emergency PCI</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>r-SAK treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous injection of single bolus 5 mg r-SAK in 3min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>saline control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous injection of 10ml saline in 3min,r-SAK and saline are the same in appearance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant Staphylokinase</intervention_name>
    <description>Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction</description>
    <arm_group_label>r-SAK treatment group</arm_group_label>
    <other_name>r-SAK single intravenous injection for early treatment of acute myocardial infarction</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Intravenous injection of placebo(normal saline ) is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction</description>
    <arm_group_label>saline control group</arm_group_label>
    <other_name>normal saline intravenous injection for early treatment of acute myocardial infarction</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18, ≦75 years old, weight ≥45kg, gender is not limited.&#xD;
&#xD;
          2. Diagnosis of acute ST-segment elevation myocardial infarction (both of the following)&#xD;
             (A) Ischemic chest pain lasting more than 30 minutes; (B) Ecg indicates ST-segment&#xD;
             elevation ≥ 0.1mV in 2 or more limb leads, or ST-segment elevation ≥ 0.2mV in 2 or&#xD;
             more adjacent chest leads;&#xD;
&#xD;
          3. Time from onset of persistent ischemic chest pain to randomization ≤12 hours;&#xD;
&#xD;
          4. Coronary angiography and/or PCI are expected to be performed within 2 hours of r-SAK&#xD;
             thrombolysis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-ST-segment elevation myocardial infarction;&#xD;
&#xD;
          2. STEMI with cardiogenic shock;&#xD;
&#xD;
          3. active bleeding or bleeding tendency, including Ⅲ, Ⅳ period history of retinopathy,&#xD;
             retinal hemorrhage, gastrointestinal tract and urinary tract hemorrhage (1 month),&#xD;
             ischemic stroke happened over the past 6 months, transient ischemic attack (TIA)&#xD;
             happened over the past 6 weeks, hemorrhagic stroke in the past, unexplained platelet&#xD;
             count &lt; 100 x 109 / L or Hemoglobin &lt;100g/L;&#xD;
&#xD;
          4. Having a history of central nervous system trauma or known intracranial aneurysm;&#xD;
&#xD;
          5. Recent (within 1 month) severe trauma, surgery or head injury;&#xD;
&#xD;
          6. Suspected aortic dissection, infective endocarditis;&#xD;
&#xD;
          7. Recent history of puncture which difficult hemostasis by compression (visceral biopsy,&#xD;
             compartment puncture);&#xD;
&#xD;
          8. Long-term use and/or current use of anticoagulant drugs;&#xD;
&#xD;
          9. Hypertension not well controlled ≥180/110mmHg;&#xD;
&#xD;
         10. Having severe hepatic and renal impairment (ALT, AST, γ-GT &gt; 2.5 times the upper limit&#xD;
             of normal value; Cr &gt; 1.5 times upper normal);&#xD;
&#xD;
         11. Known allergies to r-SAK;&#xD;
&#xD;
         12. Pregnant, breastfeeding or planned pregnancy women and male patients with family&#xD;
             planning;&#xD;
&#xD;
         13. Patients who have participated in other clinical trials in the past 3 months;&#xD;
&#xD;
         14. Other reasons that patients considered unsuitable for inclusion by researchers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunjian Li, PHD</last_name>
    <phone>+86 13701465229</phone>
    <email>lijay@njmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengsheng Chen, MD</last_name>
    <phone>+86 18112000296</phone>
    <email>cpsraikkonen@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chunjian Li, PHD</last_name>
      <email>lijay@njmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Chunjian Li, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pengsheng Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoxuan Gong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The second Affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University Medical College</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huai 'an First People's Hospital affiliated to Nanjing Medical University</name>
      <address>
        <city>Huai'an</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiwen Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Nantong Medical University</name>
      <address>
        <city>Nantong</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongzhuan Sheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renji Hospital affiliated to Shanghai Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Bu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Zhao</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou People's Hospital</name>
      <address>
        <city>Taizhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Zhu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoyan Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xuzhou Central Hospital</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wen Lu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Jiangsu People's Hospital</name>
      <address>
        <city>Yangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jing Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://en.cnki.com.cn/Article_en/CJFDTOTAL-NJYK200002004.htm</url>
    <description>Article Published in Chinese</description>
  </link>
  <results_reference>
    <citation>Correction to: Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e493. doi: 10.1161/CIR.0000000000000573.</citation>
    <PMID>29555722</PMID>
  </results_reference>
  <results_reference>
    <citation>Heusch G, Libby P, Gersh B, Yellon D, Böhm M, Lopaschuk G, Opie L. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014 May 31;383(9932):1933-43. doi: 10.1016/S0140-6736(14)60107-0. Epub 2014 May 13. Review.</citation>
    <PMID>24831770</PMID>
  </results_reference>
  <results_reference>
    <citation>Agnoletti G, Cargnoni A, Agnoletti L, Di Marcello M, Balzarini P, Pasini E, Gitti G, Martina P, Ardesi R, Ferrari R. Experimental ischemic cardiomyopathy: insights into remodeling, physiological adaptation, and humoral response. Ann Clin Lab Sci. 2006 Summer;36(3):333-40.</citation>
    <PMID>16951276</PMID>
  </results_reference>
  <results_reference>
    <citation>Townsend N, Wilson L, Bhatnagar P, Wickramasinghe K, Rayner M, Nichols M. Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J. 2016 Nov 7;37(42):3232-3245. Epub 2016 Aug 14. Erratum in: Eur Heart J. 2019 Jan 7;40(2):189.</citation>
    <PMID>27523477</PMID>
  </results_reference>
  <results_reference>
    <citation>Collen D, Lijnen HR. Thrombolytic agents. Thromb Haemost. 2005 Apr;93(4):627-30. Review.</citation>
    <PMID>15841305</PMID>
  </results_reference>
  <results_reference>
    <citation>Pulicherla KK, Kumar A, Gadupudi GS, Kotra SR, Rao KR. In vitro characterization of a multifunctional staphylokinase variant with reduced reocclusion, produced from salt inducible E. coli GJ1158. Biomed Res Int. 2013;2013:297305. doi: 10.1155/2013/297305. Epub 2013 Aug 13.</citation>
    <PMID>23998121</PMID>
  </results_reference>
  <results_reference>
    <citation>Ueshima S, Matsuo O. Development of new fibrinolytic agents. Curr Pharm Des. 2006;12(7):849-57. Review.</citation>
    <PMID>16515501</PMID>
  </results_reference>
  <results_reference>
    <citation>Yamamoto J, Kawano M, Hashimoto M, Sasaki Y, Yamashita T, Taka T, Watanabe S, Giddings JC. Adjuvant effect of antibodies against von Willebrand Factor, fibrinogen, and fibronectin on staphylokinase-induced thrombolysis as measured using mural thrombi formed in rat mesenteric venules. Thromb Res. 2000 Mar 1;97(5):327-33.</citation>
    <PMID>10709908</PMID>
  </results_reference>
  <results_reference>
    <citation>Szemraj J, Stankiewicz A, Rozmyslowicz-Szermińska W, Mogielnicki A, Gromotowicz A, Buczko W, Oszajca K, Bartkowiak J, Chabielska E. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study. Thromb Haemost. 2007 Jun;97(6):1037-45.</citation>
    <PMID>17549308</PMID>
  </results_reference>
  <results_reference>
    <citation>Vakili B, Nezafat N, Negahdaripour M, Yari M, Zare B, Ghasemi Y. Staphylokinase Enzyme: An Overview of Structure, Function and Engineered Forms. Curr Pharm Biotechnol. 2017;18(13):1026-1037. doi: 10.2174/1389201019666180209121323. Review.</citation>
    <PMID>29424308</PMID>
  </results_reference>
  <results_reference>
    <citation>Li CJ, Huang J, Yang ZJ, Cao KJ. Thrombolytic efficacy of native recombinant staphylokinase on femoral artery thrombus of rabbits. Acta Pharmacol Sin. 2007 Jan;28(1):58-65.</citation>
    <PMID>17184583</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.</citation>
    <PMID>21670242</PMID>
  </results_reference>
  <results_reference>
    <citation>Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). Glob Heart. 2018 Dec;13(4):305-338. doi: 10.1016/j.gheart.2018.08.004. Epub 2018 Aug 25. Review.</citation>
    <PMID>30154043</PMID>
  </results_reference>
  <results_reference>
    <citation>Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007 May 1;115(17):2344-51.</citation>
    <PMID>17470709</PMID>
  </results_reference>
  <results_reference>
    <citation>Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, Weiss TW, Collet JP, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheugt FWA, Lanas A, Al-Shahi Salman R, Steg PG, Huber K; ESC Working Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2017 May 14;38(19):1455-1462. doi: 10.1093/eurheartj/ehw454.</citation>
    <PMID>27789570</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Chunjian Li</investigator_full_name>
    <investigator_title>Chief leader of CCU</investigator_title>
  </responsible_party>
  <keyword>Acute Myocardial Infarction；Recombinant Staphylokinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

